The U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) has released its comprehensive list of guidance priorities for the 2027 fiscal year, signaling a major regulatory focus on the rapidly evolving sectors of artificial intelligence, robotic surgery, and diagnostic equity. By categorizing its objectives into "A-list" and "B-list" priorities, the agency provides a roadmap for medical device manufacturers, healthcare providers, and technology developers, detailing the specific areas where the FDA intends to finalize or draft new oversight frameworks. The A-list represents documents the agency fully intends to publish within the fiscal year, while the B-list consists of guidances that will be issued if resources and capacity permit. This annual transparency initiative is a cornerstone of the FDA’s commitment under the Medical Device User Fee Amendments (MDUFA V), ensuring that the industry remains aligned with the agency’s evolving safety and efficacy standards.
The Vanguard of Innovation: Artificial Intelligence and Generative AI
At the forefront of the FDA’s 2027 agenda is the regulation of Artificial Intelligence (AI) and Machine Learning (ML) in medical software. As these technologies transition from static algorithms to dynamic, iterative systems, the agency is prioritizing the finalization of guidance regarding the lifecycle management of AI-enabled device software functions. This move follows a draft version published in early 2025, which laid the groundwork for how manufacturers should handle updates, performance monitoring, and risk management throughout a product’s lifespan.
The prioritization of lifecycle management reflects the FDA’s recognition that traditional regulatory "snapshots"—where a device is cleared based on a single point in time—are insufficient for AI. Software that learns and adapts requires a continuous oversight model. By finalizing this guidance, the FDA aims to provide a predictable pathway for developers to update their algorithms without necessarily triggering a new premarket notification (510(k)) for every iteration, provided those changes fall within a pre-approved framework.
In a significant expansion of its digital health portfolio, the FDA has also placed a new emphasis on Generative AI (GenAI). Specifically, the agency intends to draft evidentiary recommendations for generative AI-enabled conversational devices designed for mental health disorders. This is a direct response to the surge in AI-driven chatbots and therapeutic platforms that utilize large language models (LLMs) to interact with patients. The agency’s move follows an August call for feedback on GenAI regulation, where industry stakeholders raised concerns about "hallucinations" (the generation of false or misleading information) and the clinical validity of AI-driven psychiatric interventions. By establishing evidentiary standards, the FDA seeks to ensure that these "digital therapists" are backed by rigorous clinical data before they reach the consumer market.
Advancing Precision in Robotically Assisted Surgical Devices
The 2027 priority list also highlights the agency’s focus on the burgeoning field of robotic surgery. The FDA aims to finalize its guidance on premarket submissions for Robotically Assisted Surgical Devices (RASD). This sector has seen exponential growth over the last decade, moving from niche urological and gynecological applications into general surgery, orthopedics, and neurosurgery.
The forthcoming final guidance is expected to refine recommendations for nonclinical testing, clinical data collection, and labeling. A key area of interest for the agency is the "human-machine interface," ensuring that surgeons are adequately trained and that the robotic systems provide sufficient tactile or visual feedback to prevent intraoperative errors. The FDA has set an ambitious goal to finalize this document within one year of the draft’s publication, reflecting the urgent need for standardized safety protocols as more manufacturers enter the robotic surgery space to compete with established incumbents.
Addressing Racial Bias and Diagnostic Inequity
One of the most socially and clinically significant items on the FDA’s B-list is the finalization of guidance for pulse oximeters. While relegated to the second-tier priority list, the document carries immense weight due to ongoing concerns regarding the accuracy of these devices in patients with darker skin pigmentation. Pulse oximeters, which measure blood oxygen levels non-invasively, have been shown in multiple studies to provide inaccurately high readings for Black and Hispanic patients, potentially leading to the delayed treatment of "occult hypoxemia."
The controversy gained national attention during the COVID-19 pandemic when pulse oximetry was a primary tool for determining hospital admissions and oxygen therapy. The FDA’s draft guidance, released in January 2025, proposed more stringent requirements for clinical trials, demanding that manufacturers include a diverse range of skin tones in their validation studies. The 2027 priority to finalize this guidance indicates the agency is moving toward a mandatory standard for diagnostic equity, ensuring that medical hardware performs reliably across the entire human spectrum of physiological diversity.
Structural Overhauls: Quality Management and Change Control
The FDA is also tackling the foundational structures of medical device manufacturing. A top A-list priority is the continued transition toward the Quality Management System Regulation (QMSR). This initiative seeks to align the FDA’s long-standing Quality System Regulation (QSR) with ISO 13485:2016, an international standard for medical device quality management. This harmonization is intended to reduce the regulatory burden on global manufacturers, allowing them to follow a single set of quality standards for both the U.S. market and international jurisdictions.
Furthermore, the agency is maintaining its focus on Predetermined Change Control Plans (PCCP). This is a holdover from the previous year’s list, representing a complex but essential piece of the regulatory puzzle. A PCCP allows a manufacturer to outline future modifications to a device—such as software patches or performance enhancements—during the initial submission. If the FDA clears the plan, the manufacturer can implement those specific changes without further regulatory filings. This "pre-approval" of future updates is seen as vital for the "Software as a Medical Device" (SaMD) industry, where the pace of innovation often outstrips traditional regulatory cycles.
Timeline and Industry Implications
The FDA is currently accepting public feedback on these proposed priorities through November 30. This comment period is a critical window for industry trade groups, such as AdvaMed and the Medical Device Manufacturers Association (MDMA), to influence the agency’s direction. Historically, industry feedback has led the FDA to shift items between the A and B lists or to clarify the scope of proposed guidances.
The 2027 fiscal year represents a pivotal moment for the CDRH. As the medical device industry increasingly overlaps with Big Tech, the agency is under pressure to maintain its gold standard of safety while not stifling the speed of innovation. The focus on AI, robotics, and diagnostic accuracy suggests that the FDA is pivoting from a reactive stance to a proactive one, attempting to build regulatory "guardrails" for technologies that are still in their formative stages.
For manufacturers, the 2027 agenda necessitates a strategic shift in R&D and regulatory affairs. Companies developing AI-enabled tools will need to prepare for more rigorous "lifecycle" oversight, while those in the surgical space must brace for more detailed clinical data requirements. Perhaps most importantly, the emphasis on pulse oximeter accuracy serves as a warning to the broader diagnostic industry: the FDA will no longer accept "one-size-fits-all" validation data that ignores the impact of race and ethnicity on device performance.
Broader Context: The MDUFA V Framework
These priorities are set against the backdrop of the MDUFA V agreement, which runs through 2027. Under this agreement, the FDA received increased funding from industry user fees in exchange for meeting specific performance goals, including faster review times and increased transparency. The publication of the A-list and B-list is a direct fulfillment of these transparency mandates.
However, the agency’s ability to clear its 2027 list will depend heavily on its internal resources. The CDRH has faced significant staffing challenges in recent years, particularly in the recruitment of specialized software engineers and data scientists needed to review complex AI algorithms. If the agency struggles to hire these experts, many items on the B-list—including the pulse oximeter guidance—could face further delays, leaving critical public health questions unanswered.
As the FDA moves toward the 2027 fiscal year, the medical device landscape is poised for a period of intense regulatory activity. By targeting the intersection of high-tech innovation and social equity, the agency is attempting to modernize its oversight for a new generation of medical technology that is smarter, more autonomous, and more inclusive. For stakeholders across the healthcare continuum, the message is clear: the era of "static" medical devices is ending, and the regulatory frameworks of the future will be as dynamic as the technologies they govern.
